Skip to main content
COSMO Pharmaceuticals N.V. logo

COSMO Pharmaceuticals N.V. — Investor Relations & Filings

Ticker · COPN ISIN · NL0011832936 LEI · 724500OX0EBQRYTVV639 SW Manufacturing
Open in API
Filings indexed 169 across all filing types
Latest filing 2022-06-28 Legal Proceedings Report
Country NL Netherlands
Listing SW COPN

About COSMO Pharmaceuticals N.V.

https://www.cosmopharma.com/

COSMO Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing and commercializing products in gastroenterology, dermatology, and healthtech. The company's portfolio is built around its proprietary MMX® technology, a platform for the targeted delivery of active ingredients in the colon. Key products include GI Genius™, an AI-powered device for endoscopy; Winlevi®, a topical treatment for acne; and therapies for inflammatory bowel diseases such as Lialda®/Mezavant® and Uceris®/Cortiment®. In addition to its own product pipeline, Cosmo provides contract manufacturing services, including process assessment, technology transfer, stability testing, and market release for pharmaceutical products.

Recent filings

Filing Released Lang Actions
Cosmo gibt Annahme des NDA-Antrags für Cortiment® MMX® in Japan bekannt
Legal Proceedings Report Classification · 99% confidence The document is titled 'Ad hoc-Mitteilung gemäss Art. 53 KR' (Ad hoc announcement according to Art. 53 KR) and is dated June 28, 2022. It announces a specific business development (acceptance of an NDA application for a drug in Japan) and includes forward-looking statements and contact information typical of a press release. This format, which is a mandatory disclosure for material, non-public information in many European jurisdictions (indicated by 'Ad hoc-Mitteilung' and 'KR' - likely referring to stock exchange regulations), does not fit the specific categories like 10-K (Annual Report), ER (Earnings Release), or CT (Call Transcript). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), the most appropriate fallback category is Regulatory Filings (RNS). The document length (7998 chars) is substantial enough that it is the primary announcement itself, not just a brief notice of publication (RPA).
2022-06-28 German
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
AGM Information Classification · 99% confidence The document explicitly states that it is announcing that shareholders approved all agenda items at today's 'virtual annual general meeting of shareholders'. It details the voting results for various proposals, such as adopting the annual accounts, approving remuneration policy, and reappointing directors. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM Information (AGM-R).
2022-05-27 English
Aktionärinnen und Aktionäre von Cosmo stimmen allen Tagungsordnungspunkten an der Generalversammlung zu
AGM Information Classification · 99% confidence The document text explicitly mentions "Generalversammlung" (General Meeting) in the title and states that shareholders voted on and approved all agenda items, including the approval of the 2021 annual financial statements, dividend distribution, and reappointment of board members and auditors. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the classification should be AGM-R (AGM Information). The document is a press release summarizing the results, which aligns with the AGM-R definition for 'Presentations and materials shared during the Annual General Meeting (AGM)'.
2022-05-27 German
Annual Report 2022
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT AND ACCOUNTS 2022' for Cosmo Pharmaceuticals. It contains a comprehensive table of contents covering the Chairman and CEO statement, corporate governance, consolidated financial statements, and the independent auditor's report. This matches the definition of an Annual Report (10-K). FY 2022
2022-03-22 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.